Correction to: Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab
Lawren VandeVrede, Renaud La Joie, Sheena Horiki, Nidhi S. Mundada, Mary Koestler, Ji-Hye Hwang, Peter A. Ljubenkov, Julio C. Rojas, Gil D. Rabinovici, Adam L. Boxer, William W. Seeley
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAmyloidosis: Diagnosis, Treatment, Outcomes · Cholinesterase and Neurodegenerative Diseases · Alzheimer's disease research and treatments
Correction to: Acta Neuropathologica (2023) 146:777–781 10.1007/s00401-023-02631-8
In this article, the cumulative dosage of aducanumab was incorrectly calculated due to failure to account for a change in the trial’s protocol. After review, the correct cumulative dose for Patient 1 is 67 mg/kg instead of 65 mg/kg, and the correct cumulative dose for Patient 2 is 68 mg/kg instead of 100 mg/kg and the patient was given aducanumab 6 mg/kg instead of 10 mg/kg.